Year: 2019

Gross Profit increased by $10.4 million, or 7.2 percent, compared to the prior year period as a result of a 3 percent increase in retail customers and a 4 percent increase in tank exchange selling locations combined with a 4.2¢ increase in margin cpg.Propane sales volume for the quarter increased 1.3 million gallons despite weather that was 4 percent warmer than the prior year as a result of the growth in customer count.Successfully completed two accretive retail acquisitions during the quarter.OVERLAND PARK, Kan., Dec. 06, 2019 (GLOBE NEWSWIRE) — Ferrellgas Partners, L.P. (NYSE:FGP) (“Ferrellgas” or the “Company”) today reported financial results for its first quarter ended October 31, 2019.For the quarter, the Company reported a net loss attributable to Ferrellgas Partners, L.P. of $45.3 million, or $0.46 per common unit, compared...

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Richard Colonno, PhD, Executive Vice President and Chief Scientific Officer Virology, will present a Plenary Lecture, “Eliminating Residual HBV Replication – A Critical Gateway to Cure” at the HEP DART Meeting on Tuesday, Dec 10, 2019 at 5:30pm HST in Kauai, HI. The presentation will include an in-depth review of interim long-term data from the ongoing Phase 2 study of ABI-H0731, Assembly’s lead core inhibitor, for the treatment of chronic Hepatitis B infection, which were reported at AASLD 2019 last month.Following the lecture, Dr. Colonno’s slides will...

SAINT LAURENT, Quebec, Dec. 06, 2019 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 415,178 common shares of the Corporation (the “Common Shares”) at a deemed price of CAD $0.73 per Common Share in payment of an aggregate of $303,080 in interest owing on the Corporation’s 8.00% convertible unsecured subordinated debentures due June 30, 2020 (the “Debentures”).Under the terms of the trust indenture governing the Debentures (the “Indenture”), the Corporation has the option to pay the semi-annual interest on the Debentures in either cash or Common Shares, subject to customary conditions set forth in the Indenture. The issuance of the Common Shares in payment of interest on the Debentures is subject to the acceptance by the TSX Venture Exchange...

SAN DIEGO, Dec. 06, 2019 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it had been awarded a $39 million sole-source contract for Geolocation Global Support Services.  The award is a five year contract that includes a base year and four one-year options, for a total value of up to $39 million.  Work on the initial $7.7M base year contract began on December 1, 2019. Kratos will provide continuous RF monitoring services for government leased bandwidth on commercial satellites and bandwidth on military satellite communications; including bandwidth identified by the Combined Space Operations Center, or CSpOC.  Kratos will also support resolving interference events through employment of mitigation strategies and geolocation activities....

MATAWAN, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) — Hovnanian Enterprises, Inc. (NYSE: HOV) (the “Company”) announced today the results of the offers to exchange (the “Exchange Offers”) by its wholly-owned subsidiary, K. Hovnanian Enterprises, Inc. (the “Issuer”), the Issuer’s outstanding 10.000% senior secured notes due 2022 (the “Old 2022 Notes”) and outstanding 10.500% senior secured notes due 2024 (the “Old 2024 Notes” and, together with the Old 2022 Notes, the “Old Notes”) for new 10.000% Senior Secured 1.75 Lien Notes due 2025 (the “New 2025 Notes”) to be issued by the Issuer, and to be guaranteed by the Company and substantially all of its subsidiaries, other than the Issuer, its home mortgage subsidiaries, certain of its title insurance subsidiaries, joint ventures and subsidiaries holding interests in joint ventures (collectively,...

SAN FRANCISCO, Dec. 06, 2019 (GLOBE NEWSWIRE) — Sutter Rock Capital Corp. (“Sutter Rock” or the “Company”) (Nasdaq:SSSS) today announced an adjustment to the conversion rate of its 4.75% Convertible Senior Notes due 2023 (the “Notes”) as a result of the Company’s recently completed modified “Dutch Auction” tender offer to repurchase shares of its common stock (the “Tender Offer”) and its cash dividend payable on December 12, 2019.Effective as of December 2, 2019, the conversion price applicable to the Notes has been adjusted to $10.39 per share (96.2265 shares of the Company’s common stock per $1,000 principal amount of Notes) from an initial conversion price of $10.72 per share (93.2836 shares of the Company’s common stock per $1,000 principal amount of Notes). The adjustment to the conversion rate of the Notes was made pursuant...

MONTREAL, Dec. 06, 2019 (GLOBE NEWSWIRE) — Siyata Mobile Inc. (the “Company” or “Siyata”) (TSX-V:SIM / OTCQX:SYATF) is pleased to announce the appointment of Mr. Richard Hoy to its Board of Directors. With over 30 years experience, Mr. Hoy has a highly successful track record of leading and building enterprise sales teams to deliver accountable and significant revenue growth.  He is appointed as an active board member overseeing enterprise sales growth, opening direct customer and carrier relationships, corporate governance and strategy.For the last 7 years, Mr. Hoy was the SVP of Operations of Ledcor, responsible for the Telecom Division in Canada including sales, service, engineering, and build functions. During his tenure, Ledcor grew significantly through profit, revenue, team members, customers, markets...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATESVANCOUVER, British Columbia, Dec. 06, 2019 (GLOBE NEWSWIRE) — Lumina Gold Corp. (TSXV: LUM) (OTCQX: LMGDF) (the “Company” or “Lumina”) is pleased to announce that it has increased the size of its proposed non-brokered private placement previously announced on December 2, 2019, to up to 18.0 million common shares in the capital of Lumina (the “Shares”) at a price of C$0.50 per Share to raise gross proceeds of up to approximately C$9.0 million (the “Private Placement”). Ross J. Beaty has agreed to subscribe for C$4.85 million of the private placement. Assuming the Offering size is exactly C$9.0 million and Mr. Beaty subscribes for C$4.85 million of the Offering, Mr. Beaty’s ownership of Lumina will increase from 17.95% to 19.90% on a non-diluted...

NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), and Inceptua Medicines Access (a business unit of the Inceptua Group), a global pharmaceutical company and service partner, today announced that they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for...

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of triple therapy data presentations, at the upcoming 61st American Society of Hematology (ASH) annual meeting and exposition, to be held December 7 – 10, 2019, at the Orange County Convention Center in Orlando, FL.Presentations at the ASH 2019 meeting include the following:Oral Presentation Details:Title: A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Publication Number: 360Oral Session: 642. CLL: Therapy, excluding Transplantation: Combination and Novel TreatmentSession Date and Time:  Sunday, December 8, 2019; 7:30 AM – 9:00 AM ETPresentation Time: 8:45 AM ETLocation: Orange County Convention Center, Hall E1Presenter: Paul M. Barr,...